Statin use and outcomes of oncological treatment for castration-resistant prostate cancer
Authors:
Open Access
- 1 November 2023
- journal article
- research article
- Published by Springer Nature in Scientific Reports
- Vol. 13 (1) , 1-9
Abstract
To compare the effect of statin use in relation to castration-resistant prostate cancer (CRPC) treatment, we assessed the risk of ADT-treated PCa-patients to initiate CRPC treatment by statin use and the outcomes of CRPC treatment by statin use. Our study cohort consisted of 1169 men who participated in the Finnish Randomized Study of Screening for Prostate Cancer (FinRSPC) and initiated androgen deprivation therapy (ADT) during the follow-up (1996–2017). Statin use was associated with slightly decreased risk of initiating CRPC treatment (HR 0.68; 95% CI 0.47–0.97) with a 5.7 years’ median follow-up until CRPC for non-users and 7.5 years for statin users. The risk of discontinuation of first or second line CRPC treatment due to inefficacy was not modified by statin use and the results remained similar in subgroup analysis assessing separately patients treated with taxans or androgen receptor signaling inhibitors. We observed an inverse association between statin use and the risk of initiation of the CRPC treatment. No beneficial risk modification by statin use during CRPC treatment was observed. These results suggest that statins might be beneficial during hormone-sensitive phase but not in the later phases of prostate cancer treatment.Keywords
Funding Information
- Suomen Kulttuurirahasto
- Emil Aaltosen Säätiö
This publication has 31 references indexed in Scilit:
- Statin Use and Prostate Cancer Survival in the Finnish Randomized Study of Screening for Prostate CancerEuropean Urology Focus, 2017
- Ror2 signaling regulates Golgi structure and transport through IFT20 for tumor invasivenessScientific Reports, 2017
- Statin derivatives as therapeutic agents for castration-resistant prostate cancerCancer Letters, 2016
- Additive inhibitory effects of simvastatin and enzalutamide on androgen-sensitive LNCaP and VCaP prostate cancer cellsBiochemical and Biophysical Research Communications, 2016
- Influence of Statins on Survival Outcome in Patients with Metastatic Castration Resistant Prostate Cancer Treated with Abiraterone AcetatePLOS ONE, 2016
- Statin Use at the Time of Initiation of Androgen Deprivation Therapy and Time to Progression in Patients With Hormone-Sensitive Prostate CancerJAMA Oncology, 2015
- Statin use not associated with improved outcomes in patients treated with brachytherapy for prostate cancerBrachytherapy, 2015
- Prostate Cancer Mortality in the Finnish Randomized Screening TrialJNCI: Journal of the National Cancer Institute, 2013
- The association of statins and taxanes: an efficient combination trigger of cancer cell apoptosisBritish Journal of Cancer, 2012
- Effect of statin use on biochemical outcome following radical prostatectomyBJU International, 2011